Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy AbbVie (ABBV) stock
Learn how to easily invest in AbbVie stock.
AbbVie Inc is a drug manufacturers-general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars. AbbVie employs 48,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in AbbVie
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ABBV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- ABBV shares summary
- Compare share dealing platforms
- Is ABBV stock a buy or sell?
- Stock performance over time
- Can I short ABBV shares?
- Is ABBV suitable for ethical investing?
- Are ABBV shares over-valued?
- AbbVie's financials
- How volatile are ABBV shares?
- Does AbbVie pay a dividend?
- Other common questions
AbbVie stock price (NYSE: ABBV)Use our graph to track the performance of ABBV stocks over time.
AbbVie shares at a glance
|Latest market close||$112.36|
|52-week range||$77.49 - $118.33|
|50-day moving average||$115.01|
|200-day moving average||$110.51|
|Wall St. target price||$124.08|
|Dividend yield||$4.96 (4.24%)|
|Earnings per share (TTM)||$2.91|
Buy AbbVie shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AbbVie price performance over time
|1 week (2021-07-13)||N/A|
|1 month (2021-06-24)||-2.07%|
|3 months (2021-04-23)||0.88%|
|6 months (2021-01-20)||N/A|
|1 year (2020-07-20)||N/A|
|2 years (2019-07-20)||N/A|
|3 years (2018-07-20)||N/A|
|5 years (2016-07-20)||N/A|
Is AbbVie under- or over-valued?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, AbbVie shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.5 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$50.2 billion|
|Operating margin TTM||32.67%|
|Gross profit TTM||$31.7 billion|
|Return on assets TTM||8.48%|
|Return on equity TTM||163.56%|
|Market capitalisation||$207.6 billion|
TTM: trailing 12 months
Shorting AbbVie shares
There are currently 13.8 million AbbVie shares held short by investors – that's known as AbbVie's "short interest". This figure is 6.7% down from 14.8 million last month.
There are a few different ways that this level of interest in shorting AbbVie shares can be evaluated.
AbbVie's "short interest ratio" (SIR)
AbbVie's "short interest ratio" (SIR) is the quantity of AbbVie shares currently shorted divided by the average quantity of AbbVie shares traded daily (recently around 5.7 million). AbbVie's SIR currently stands at 2.42. In other words for every 100,000 AbbVie shares traded daily on the market, roughly 2420 shares are currently held short.
However AbbVie's short interest can also be evaluated against the total number of AbbVie shares, or, against the total number of tradable AbbVie shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbbVie's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AbbVie shares in existence, roughly 10 shares are currently held short) or 0.0079% of the tradable shares (for every 100,000 tradable AbbVie shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbbVie.
Find out more about how you can short AbbVie stock.
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||34.86|
|Total ESG percentile||65.78|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||3|
AbbVie share dividends
Dividend payout ratio: 46.01% of net profits
Recently AbbVie has paid out, on average, around 46.01% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.42% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 4.42% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $4.96 per share.
While AbbVie's payout ratio might seem fairly standard, it's worth remembering that AbbVie may be investing much of the rest of its net profits in future growth.
AbbVie's most recent dividend payout was on 15 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 July 2021 (the "ex-dividend date").
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as $77.4908 up to $118.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.8009. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. .
Stocks similar to AbbVie
AbbVie in the news
JDIV: Large Cap Dividend ETF Review
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
Global company events calendar - next 7 days
Frequently asked questionsWhat percentage of AbbVie is owned by insiders or institutions?
Currently 0.125% of AbbVie shares are held by insiders and 69.02% by institutions. How many people work for AbbVie?
Latest data suggests 48,000 work at AbbVie. When does the fiscal year end for AbbVie?
AbbVie's fiscal year ends in December. Where is AbbVie based?
AbbVie's address is: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 What is AbbVie's ISIN number?
AbbVie's international securities identification number is: US00287Y1091 What is AbbVie's CUSIP number?
AbbVie's Committee on Uniform Securities Identification Procedures number is: 00287T100
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert